This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Chemed (CHE) Beats on Q1 Earnings & Revenues, Retains View
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q1.
MedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHE
by Zacks Equity Research
On a positive note, the broader healthcare looks delighted with the massive tax cuts. Also, the scenario within the Medical Device space seems equally bright.
Chemed (CHE) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q4.
Will Envision Healthcare's Growth Strategies Help the Stock?
by Zacks Equity Research
Envision Healthcare (EVHC) is expected to gain from is a number of long term growth strategies.
New Year to Bring Back MedTech Tax, 3 Stocks Unfazed
by Zacks Equity Research
Investors are apprehensive about the re-enactment of MedTech Tax and related concerns, despite raking in returns from other sectors.
4 Reasons Why Envision Healthcare (EVHC) Looks Dull
by Zacks Equity Research
Envision Healthcare continues to suffer from low patient volumes, increased leverage, high operating expense and a weak operating environment.
Zimmer Biomet Strong on Positive Data From PROGRESS II Study
by Zacks Equity Research
Zimmer Biomet (ZBH) consistently endeavors to improve its knee business.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.
Haemonetics Banks on Hospital Business, Competition Rife
by Zacks Equity Research
For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.
Zacks.com highlights: Lululemon Athletica, Chemed, Baxter International, NVR and Copart
by Zacks Equity Research
Zacks.com highlights: Lululemon Athletica, Chemed, Baxter International, NVR and Copart
5 of the Best Efficient Stocks to Strengthen Your Portfolio
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
4 Growth Stocks to Pick From a Choppy MedTech Market
by Zacks Equity Research
In the wake of the volatile political scenario and taking a few favorable metrics into account, these MedTech stocks stand out as the most suitable picks.
DaVita (DVA) Surges: Stock Moves 13.6% Higher
by Zacks Equity Research
DaVita (DVA) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes
Chemed Banks on Roto-Rooter Sales, Focuses on Vitas Revival
by Zacks Equity Research
Chemed (CHE) continues to display robust performance in Roto-Rooter business on strength in core plumbing and drain cleaning service segments.
Align Technology Rides High on InvisAlign & Strategic Pacts
by Zacks Equity Research
Rising demand for InvisAlign products in the global teen market and the distribution agreement with Patterson Dental are major upsides for Align (ALGN).
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
by Zacks Equity Research
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
5 of the Most Efficient Stocks to Boost Your Portfolio
by Tirthankar Chakraborty
Company with a favorable efficiency level generally provides impressive returns as it is believed to be positively correlated with the stock's price performance.
Envision Healthcare Down More Than 50% This Year, Here's Why
by Zacks Equity Research
Envision Healthcare (EVHC) seems to be bogged down by soft patient volumes, increasing expenses and high leverage.
Chemed (CHE) Up 13.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Envision Healthcare Hits 52-Week Low on Q3 Miss, Grim View (Revised)
by Zacks Equity Research
Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.
Envision Healthcare Hits 52-Week Low on Q3 Loss, Grim View
by Zacks Equity Research
Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.
Envision Healthcare Continues to Expand Physician Services
by Zacks Equity Research
Envision Healthcare's (EVHC) numerous acquisitions and management changes are aimed at growing its physician services segment.
STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat
by Zacks Equity Research
STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen Corporation's (ABC) expects tepid performance from PharMEDium due to pricing pressure in the generic drug space.
CVS Health Gains on Pharmacy Services, Retail Remains a Drag
by Zacks Equity Research
CVS Health (CVS) benefits from strong Pharmacy Services numbers and continues to deliver solid PBM selling seasons. Retail performance stays sluggish on several headwinds.